公开(公告)号：US20170107209A1

公开(公告)日：2017-04-20

申请号：US15391645

申请日：2016-12-27

申请人： IMAGO PHARMACEUTICALS, INC.

发明人： Hing L. SHAM ,  Roy K. Hom ,  Andrei W. Konradi ,  Gary D. Probst ,  Simeon Bowers ,  Anh Truong ,  R. Jeffrey Neitz ,  Jennifer Sealy ,  Gregely Toth

IPC分类号： C07D409/04 ,  C07D487/04 ,  C07D413/14 ,  C07D417/14 ,  C07D417/04 ,  C07D413/04 ,  C07D409/14 ,  C07D471/04

CPC分类号： C07D409/04 ,  A61K31/381 ,  A61K31/401 ,  A61K31/4196 ,  A61K31/4245 ,  A61K31/433 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/498 ,  A61K31/4985 ,  A61K31/519 ,  C07D409/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04

摘要： The present disclosure provides inhibitors of c-Jun N-terminal kinases (JNK) having a structure according to the following formula: or a salt or solvate thereof, wherein ring A, Ca, Cb, Z, R5, W and Cy are defined herein. The disclosure further provides pharmaceutical compositions including the compounds of the present disclosure and methods of making and using the compounds and compositions of the present disclosure, e.g., in the treatment and prevention of various disorders, such as Alzheimer's disease.

公开(公告)号：US09796706B2

公开(公告)日：2017-10-24

申请号：US15391645

申请日：2016-12-27

申请人： IMAGO PHARMACEUTICALS, INC.

发明人： Hing L. Sham ,  Roy K. Hom ,  Andrei W. Konradi ,  Gary D. Probst ,  Simeon Bowers ,  Anh Truong ,  R. Jeffrey Neitz ,  Jennifer Sealy ,  Gergely Toth

IPC分类号： C07D409/04 ,  C07D409/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  A61K31/381 ,  A61K31/433 ,  A61K31/401 ,  A61K31/4196 ,  A61K31/4245 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/498 ,  A61K31/4985 ,  A61K31/519

CPC分类号： C07D409/04 ,  A61K31/381 ,  A61K31/401 ,  A61K31/4196 ,  A61K31/4245 ,  A61K31/433 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/498 ,  A61K31/4985 ,  A61K31/519 ,  C07D409/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04

摘要： The present disclosure provides inhibitors of c-Jun N-terminal kinases (JNK) having a structure according to the following formula: or a salt or solvate thereof, wherein ring A, Ca, Cb, Z, R5, W and Cy are defined herein. The disclosure further provides pharmaceutical compositions including the compounds of the present disclosure and methods of making and using the compounds and compositions of the present disclosure, e.g., in the treatment and prevention of various disorders, such as Alzheimer's disease.